IteraMed is advised by notable drug discoverers:

John Carson joined the pharmaceutical industry in 1961, after graduating from the University of Illinois (Ph.D.) and the University of Nebraska (B.S.).  He is a recognized expert in pyrrole chemistry and has been called up for advice by generations of synthetic chemists.  His promotion in 1976 to Senior Research Fellow enabled him to pursue medicinal chemistry with a relatively free hand.  Over the course of his forty-three year career, fourteen different drugs emerged from his lab, which advanced to drug safety evaluation.  Besides the marketed drugs, two others were evaluated in Phase II clinical trials.  He has worked in areas of hypertension, angina, anxiety and depression, but his work in pain and inflammation is most notable, with important discoveries in the area of delta opioid modulators as recently as 2006. 

John's early interest in pyrrole chemistry led to the invention of two marketed anti-inflammatory drugs: Tolectin® (Tolmetin sodium) and Zomax® (Zomepirac sodium).  In recognition of his scientific and bottom-line contributions, John has been the recipient of several prestigious awards.  In 1972, he was awarded the inaugural Philip B. Hofmann Research Scientist Award for the conception and synthesis of the Tolectin series, of non-steroidal anti-inflammatory compounds for the treatment of rheumatoid arthritis.   He also received the preeminent scientific award in 1986 for his discovery of Zomax.  He received the Johnson Medal in 1978 for his contributions to the successful commercialization of a product.  More recently, he was also honored by the Temple University School of Pharmacy in 2002-2003 as the Centennial Lecture for “An Outstanding Record of Achievement in the Pharmaceutical Industry”.

Harold Almond's Ph.D. thesis involved the synthesis of substrates for alpha-chymotrypsin and the determination of its kinetic constants.  He joined McNeil Laboratories (1960) and synthesized compounds of potential pharmaceutical use.  McNeil's first NMR had just been acquired, and Dr. Almond tutored its use to the other chemists.  In 1964 he became the leader of the company’s first analytical group.  In subsequent years he launched McNeil's first MS, first HPLC, first computerized compound-collection inventory system and first computer/graphics system for computational chemistry and molecular modeling. 

After 1976 Dr. Almond devoted full time to computer assisted drug design.  This involved working with pharmacologists and computer scientists and partnering with medicinal chemists to guide their work toward more potent compounds with fewer side effects. He made significant contributions to projects involving - Thrombogenic Collagen-Mimetic Peptides; Urotensin-II  Antagonists; Alpha2-Adrenoceptor Agonists;  Anticonvulsant Agents; Non-Opiate Antinociceptive Agents; Calcium Entry-Blockers;  Inhibitors of Thrombin; Cathepsin-S; Tryptase; Cathepsin-G; Chymase; Alpha-Chymotrypsin; Conformational Studies; NMR Rate Studies; and a program using Gaussian Docking Functions.